Abiopharma

EVOLUS, INC. (EOLS) Reports the reporting period Financial Results EVOLUS, INC. (EOLS) announced its financial results for the period ending the reporting period. Key Financial Highlights:

• Revenue: 73137
• Net Income: $72,747
• EPS: Not disclosed
• Cash and equivalents: 49792
  • The company’s key performance indicators demonstrated continued momentum during the first quarter, reflecting increasing customer penetration, strong reorder behavior, and the scalability of Evolus’ digitally enabled commercial platform.◦Total purchasing accounts increased by nearly 500 in the first quarter. Since launch, more than 18,100 customers have purchased from Evolus, with approximately 3,500 purchasing Evolysse®, driving U.S. account penetration above 60%. Customer reorder rates are approximately 71%2, reflecting strong engagement and retention. ◦Members in the Evolus Rewards™ consumer loyalty program grew by nearly 75,000 during the quarter to approach
  • 5 million3, representing a total increase of 27% as compared to the first quarter of
  • ◦Total Evolus Rewards™ redemptions for the quarter grew and reached an all